ReGen Biologics Employs Industry Veteran To Lead Training

HACKENSACK, N.J.–(BUSINESS WIRE)–ReGen Biologics (OTC: RGBO), which manufactures and distributes a meniscus implant for use in arthroscopic surgery to address the most common form of knee injury, has hired an executive with nearly two decades of orthopaedics experience to lead the company’s surgeon education and training program.

Cameron McCaa, as Director of Education and Training, will lead efforts already underway to train U.S. surgeons on the Menaflex™ collagen meniscus implant. The device is inserted during knee meniscus surgery to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus.

“Recruiting a seasoned industry executive to oversee the surgeon training programs demonstrates ReGen’s commitment to ensuring that surgeons, who already have shown a high interest in the Menaflex device, are fully informed about the role it plays in meniscus preservation efforts,” said ReGen Chairman and CEO Gerald E. Bisbee Jr., Ph.D.

ReGen has undertaken training throughout the United States to provide surgeons with practical guidance on insertion and use of the Menaflex device.

Mr. McCaa noted, “This device, which was cleared last year by the U.S. Food and Drug Administration, has been in use in Europe for a number of years. Part of my mission will be to ensure U.S. surgeons learn of patient results in Europe, as well as in the clinical studies here in the United States.”

In addition to overseeing the surgeon training programs, Mr. McCaa will lead training efforts for sales staff and other employees.

“Cam’s extensive business background in orthopedic sales and marketing, plus his history with meniscus preservation while working with Cryolife, offer a great combination of practical and academic insight,” commented Jeff Chandler, ReGen’s Senior Vice President of Sales and Marketing.

Mr. McCaa previously worked for End Range of Motion Improvement, Inc., Infinity Orthopaedics, LLC, and Cryolife, Inc. He received a bachelor of science in mechanical engineering from Christian Brothers University and a Master of Science degree in mechanical and biomedical engineering from the University of Texas.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button